|
|
| | Nsc97113 Basic information |
| Product Name: | Nsc97113 | | Synonyms: | Nsc97113;N6-Methyl-xylo-adenosine;9H-Purin-6-amine, N-methyl-9-β-D-xylofuranosyl-;(2R,3R,4R,5R)-2-(hydroxymethyl)-5-(6-(methylamino)-9H-purin-9-yl)tetrahydrofuran-3,4-diol | | CAS: | 65494-95-3 | | MF: | C11H15N5O4 | | MW: | 281.27 | | EINECS: | | | Product Categories: | | | Mol File: | 65494-95-3.mol |  |
| | Nsc97113 Chemical Properties |
| Boiling point | 649.1±65.0 °C(Predicted) | | density | 1.85±0.1 g/cm3(Predicted) | | pka | 13.12±0.70(Predicted) |
| | Nsc97113 Usage And Synthesis |
| Uses | N6-Methyl-xylo-adenosine is an adenosine analog. Adenosine analogs mostly act as smooth muscle vasodilators and have also been shown to inhibit cancer progression. Its popular products are adenosine phosphate, Acadesine (HY-13417), Clofarabine (HY-A0005), Fludarabine phosphate (HY-B0028) and Vidarabine (HY-B0277)[1]. | | Definition | ChEBI: Adenosine, N-methyl- is a purine nucleoside. | | References | [1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005
[2] Man S, et al. Potential and promising anticancer drugs from adenosine and its analogs. Drug Discov Today. 2021 Jun;26(6):1490-1500. DOI:10.1016/j.drudis.2021.02.020 |
| | Nsc97113 Preparation Products And Raw materials |
|